Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Pulmonary Hypertension in Sickle Cell Disease (walk-PHaSST)
NCT00492531Phase 2Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ASP-001 in pulmonary hypertension (PH) (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Change in Exercise Capacity as Assessed by 6 Minute Walk. Started Jun 2007; status: terminated.
02
Drugs
ASP-001
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00492531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492531.